Novel Utilization of Blood Work Monitoring (NavDx) for Early Detection of Cervical and Anal Cancers
ISEF · 2024 Translational Medical Science
Overview
HPV driven oropharyngeal squamous cell carcinoma (OPSCC) linked cancers kill upwards of 40,000 people each year. In order for early detection and treatment to be administered, the NavDx blood test was created to detect OPSCC cancers at the earliest stage, leading to earlier treatment times and better outcomes. Cervical and anal cancers impact upwards of 12,000 people each year, and without early detection, around 4,000 lives are lost each year. By extrapolating this NavDx test to cervical and anal cancers of the same characteristics, it is determined that 96% of these cancers could be treated early. This project examines the efficacy of extrapolating this test to cervical and anal cancers in order to bring about a new efficient testing method for recurring cancers.
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2023
Non-Invasive Pre-Screening Approach for Early Detection of the Human Papillomavirus (HPV) to Aid in Cervical Cancer Prevention in Underrepresented Demographics
ISEF · 2016
Predicting a Cancerous Outcome: Creating a Novel Test for Assessing Risk of Human Papilloma Virus-Associated Oropharyngeal Cancer
ISEF · 2025
Cancer Testing: Disco Diagnosis
ISEF · 2026
Machine Learning Biomarker Discovery and AI-Based Protein Design for Low-Cost Oral Cancer Screening
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair